Thanks Bull. I can completely understand investors like yourself...

Thanks Bull.

I can completely understand investors like yourself wanting answers to these questions, they are often important bench marks & performance indicators.

CGL is a complicated investment due to the infancy of it's targeted industries.

CGL has always been a high risk investment & remains so to this day. Last weeks BioHealth binding-MOU announcment has significantly de-risked the company however there is still hard work to be done.

I believe forecasting revenue figures at this early stage would be a mistake, particurly after a difficult first harvest last year.

I'd like to see the company finalize the re-compliance process & re-list before anything

Upon re-lisitng we then need to see CGL focus their energy on the manufacturing of initial inventory to coincide with a well executed plan into the Australian/Asian markets.

Hopefully at the same time we see some favourable news regarding harvests.

I'd be okay with the company testing the overseas markets & perfecting a harvest before releasing any forecast figures.

Better to pleasantly suprise the market than over promise.

Perhaps 2020 will be the year to set firmer targets?

Perhaps CGL management are planning to release figures shortly? No idea really,

Not everyone is going to share my analysis of CGL but I'm really just trying to take the common sense approach to a highly speculative stock & apply logic when I can.

I welcome yours & any other investors opinions Bull regarding this.

Dan.